肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Sci Rep：卵巢癌对顺铂耐药的新机制

2017-05-08 MedSci MedSci原创

卵巢癌顺铂耐药
关注

高级别浆液性卵巢癌是最常见的卵巢癌。虽然手术和铂类-紫杉烷化疗的组合提供了有效的治疗，但耐药性常常发生，导致不良结果。近期，一项发表在杂志Sci Rep上的研究旨在阐明其耐药性的分子机制。研究者们从患者的恶性腹水细胞中检查了与高级别浆液性卵巢癌耐药性发展相关的DNA甲基化和转录组学变化。与大规模转录组变化相一致，顺铂耐药与位于基因组基因间区域的几个CpG位点的超甲基化丧失相关。转录组和CpG甲基化

高级别浆液性卵巢癌是最常见的卵巢癌。虽然手术和铂类-紫杉烷化疗的组合提供了有效的治疗，但耐药性常常发生，导致不良结果。


近期，一项发表在杂志Sci Rep上的研究旨在阐明其耐药性的分子机制。

研究者们从患者的恶性腹水细胞中检查了与高级别浆液性卵巢癌耐药性发展相关的DNA甲基化和转录组学变化。

与大规模转录组变化相一致，顺铂耐药与位于基因组基因间区域的几个CpG位点的超甲基化丧失相关。

转录组和CpG甲基化对响应顺铂治疗的敏感性和细胞耐药的变化很小，这表明，翻译后机制在调节细胞死亡或存活的重要性。

耐药细胞对高浓度顺铂的反应揭示了耐药性潜在关键驱动因素，如KLF4的转录组学变化。其中最强烈的变化也诱导了耐药细胞中的IL6的表达，并且其表达在对顺铂的反应中进一步增加。

此外，IL6信号传导的其他几个成分也受到影响，这也进一步支持了其对恶性转化和卵巢癌耐药性发展的重要性。

原始出处：
Lund RJ1, Huhtinen K , et al. DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer. Sci Rep. 2017 May 4;7(1):1469. doi: 10.1038/s41598-017-01624-4. 

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1737507, encodeId=56771e375073a, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Aug 10 11:46:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958236, encodeId=a09c195823603, content=<a href='/topic/show?id=9fff10012688' target=_blank style='color:#2F92EE;'>#顺铂耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100126, encryptionId=9fff10012688, topicName=顺铂耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 01 23:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=195988, encodeId=194919598818, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed May 10 06:06:41 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=195646, encodeId=a63419564676, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue May 09 06:44:33 CST 2017, time=2017-05-09, status=1, ipAttribution=)]
    2017-08-10 ms3153534357578991

    #铂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1737507, encodeId=56771e375073a, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Aug 10 11:46:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958236, encodeId=a09c195823603, content=<a href='/topic/show?id=9fff10012688' target=_blank style='color:#2F92EE;'>#顺铂耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100126, encryptionId=9fff10012688, topicName=顺铂耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 01 23:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=195988, encodeId=194919598818, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed May 10 06:06:41 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=195646, encodeId=a63419564676, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue May 09 06:44:33 CST 2017, time=2017-05-09, status=1, ipAttribution=)]
    2017-09-01 yeye5224612

    #顺铂耐药#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1737507, encodeId=56771e375073a, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Aug 10 11:46:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958236, encodeId=a09c195823603, content=<a href='/topic/show?id=9fff10012688' target=_blank style='color:#2F92EE;'>#顺铂耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100126, encryptionId=9fff10012688, topicName=顺铂耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 01 23:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=195988, encodeId=194919598818, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed May 10 06:06:41 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=195646, encodeId=a63419564676, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue May 09 06:44:33 CST 2017, time=2017-05-09, status=1, ipAttribution=)]
    2017-05-10 龙胆草

    学习了，谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1737507, encodeId=56771e375073a, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Aug 10 11:46:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958236, encodeId=a09c195823603, content=<a href='/topic/show?id=9fff10012688' target=_blank style='color:#2F92EE;'>#顺铂耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100126, encryptionId=9fff10012688, topicName=顺铂耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 01 23:46:00 CST 2017, time=2017-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=195988, encodeId=194919598818, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed May 10 06:06:41 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=195646, encodeId=a63419564676, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue May 09 06:44:33 CST 2017, time=2017-05-09, status=1, ipAttribution=)]
    2017-05-09 龙胆草

    学习了，谢谢分享

    0

相关资讯

卵巢癌的希望来临

在本周的科学会议上，研究人员报告指出在开发卵巢癌免疫治疗方面取得了一些进展。同时他们也概述了在实施有效治疗癌症前所存在的一些挑战。

Nat Genet：基因组分析显示：卵巢癌有7种疾病亚群

通过基因组分析发现，卵巢癌可分为7个亚群。最新研究显示，识别卵巢癌组织类型，体细胞基因组中的点突变和结构变异是强大且具有判别性质的生物标志物。

Cancer Causes & Control：高血压治疗或可影响卵巢癌预后

新的研究表明，女性卵巢癌的预后受一系列不可预期因素的影响。

Obstet Gynecol：腹腔镜与开腹手术在新辅助化疗后的卵巢癌减瘤术中的比较！

新辅助化疗后选择用于腹腔镜进行肿瘤细胞减灭术的卵巢癌患者与开腹手术进行肿瘤细胞减灭术的患者3年生存率相近。腹腔镜患者术后住院时间有所缩短，而术后再入院率和围手术期死亡风险与开腹手术相似。

Nat Biomed Eng：癌症早筛再获进步，纳米技术或将卵巢癌筛查提前5个月！

卵巢癌是女性生殖系统常见的三大恶性肿瘤之一，其中的一种分型——卵巢上皮癌的死亡率更是居于妇科肿瘤的首位。卵巢癌根据不同的发展阶段共分为四期，而由于早期症状不明显，往往难以发现和治疗，等到晚期时，患者的5年生存率就会大打折扣。根据美国癌症协会（ACS）的官方数据，如果能在一期的时候就进行及时的诊断和治疗，那么患者的5年生存率能够达到92%。

浙大医学院附属妇产科医院谢幸教授：可用基因检测筛查卵巢癌并指导用药

过去１０年间，我国卵巢癌发病率增加３０％，死亡率增加１８％。中华医学会妇科肿瘤学分会候任主任委员、中华医学会妇产科学分会常委、浙江大学医学院附属妇产科医院谢幸教授说，卵巢癌是“隐形杀手”，七成以上卵巢癌病例就诊时已为晚期。卵巢癌的发病原因至今不明，但近年研究发现，其中部分病人发病与基因突变有关。 作为妇科常见癌，卵巢癌是妇科恶性肿瘤的“凶”癌之一。相关数据显示，全球每年有超